Liquidia Technologies

General Information


We are a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. We are currently focused on the development of two product candidates for which we hold worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension, or PAH, and LIQ865 for the treatment of local post-operative pain. Our lead product candidate, LIQ861, is being evaluated in a Phase 3 trial. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies.

Employees: 60
Founded: 2004
Contact Information
Address 419 Davis Drive, Suite 100, Morrisville, NC 27560, US
Phone Number (919) 328-4400
Web Address
View Prospectus: Liquidia Technologies
Financial Information
Market Cap $166.3mil
Revenues $6.5 mil (last 12 months)
Net Income $-46.8 mil (last 12 months)
IPO Profile
Symbol LQDA
Exchange NASDAQ
Shares (millions): 4.5
Price range $11.00 - $11.00
Est. $ Volume $50.0 mil
Manager / Joint Managers Jefferies/ Cowen
CO-Managers Needham & Company/ Wedbush PacGrow
Expected To Trade: 7/26/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change